Blood Culture Tests Market Size - By Product (Instrument, Consumable), Method (Conventional, Automated), Technology (Culture, Molecular, Proteomic), Application (Bacterial, Fungal Infections), End-use (Diagnostic Center, Hospital), & Forecast 2024-2032

Blood Culture Tests Market Size - By Product (Instrument, Consumable), Method (Conventional, Automated), Technology (Culture, Molecular, Proteomic), Application (Bacterial, Fungal Infections), End-use (Diagnostic Center, Hospital), & Forecast 2024-2032

Blood Culture Tests Market Size

Blood Culture Tests Market was valued at USD 5.8 billion in 2023 and is estimated to showcase about 7.9% CAGR between 2024 and 2032. Driven by the rising incidence of bacterial infections and other related conditions is likely to elevate the need for blood culture tests as confirmatory diagnostic procedures. Furthermore, technological advancements, particularly in automated systems, are improving the efficiency and accuracy of blood culture tests.
 

Rising global healthcare expenditure is facilitating the adoption of advanced diagnostic solutions, while the trend towards point of care testing, which is estimated to account for USD 78.3 billion by 2032, is influencing the development of faster and more convenient options, thereby accelerating market growth.
 

Blood Culture Tests Market Trends

Blood culture tests play a pivotal role in the diagnosis and management of bloodstream infections, providing critical insights for effective medical intervention. As healthcare continues to evolve, several trends are shaping the increasing demand for sepsis diagnostics, reflecting a growing recognition of their significance in infectious disease diagnostics and patient care.  
 

• As per estimates from the World Health Organization (WHO), out of every 100 patients admitted under acute care in hospitals, 15 patients in low-and-middle-income countries and 7 patients in high-income countries will be infected by any one of the hospital-acquired infections during their hospital stay.  
   
• Moreover, rapid, and reliable diagnostic tools not only enable healthcare professionals to identify infection early in its course but also facilitates targeted and timely treatment strategies.
   
• Governments around the globe are increasingly acknowledging the profound impact of infectious diseases on public health, prompting a surge in initiatives aimed at mitigating their effects. For instance, in November 2022, the U.S. Centers for Disease Control and Prevention (CDC) initiated a USD 3.2 billion grant program to fortify the nationwide public health infrastructure.
   

Blood Culture Tests Market Analysis

The consumables segment garnered USD 3.5 billion revenue in 2023.
 

• Within the consumables category, there is a noticeable trend towards an increased emphasis on the quality of culture media. As the accuracy of blood culture tests depends on the effectiveness of the culture medium, manufacturers are investing in developing high-quality, specialized media to enhance diagnostic precision.
   
• Moreover, with the rising importance of point-of-care testing, there is a notable trend towards the development of consumables tailored for on-site diagnostics. This trend aims to address the demand for rapid results in various healthcare settings, reducing the turnaround time for blood culture testing.
   

Therefore, the market is poised to meet the evolving demands of accurate and efficient diagnostic solutions in the healthcare industry.
 

The conventional method segment held approximately 62% share of the blood culture tests market in 2023.
 

• Conventional blood culture methods are evolving with the integration of molecular techniques. The use of molecular assays alongside traditional culturing enhances the sensitivity and specificity of pathogen identification, providing more comprehensive diagnostic insights.
   
• Conventional blood culture testing is increasingly being complemented by rapid diagnostic tests. This synergy allows for a more comprehensive approach, combining the sensitivity of blood culture methods with the speed of rapid tests, thereby addressing the need for both accuracy and efficiency.
   

Thus, integration of molecular techniques, advancements in culture media, optimization of incubation conditions, and adaptations for point-of-care settings collectively contribute to the resilience and relevance of conventional methods in the diagnosis of bloodstream infections.
 

Based on technology, the blood culture tests market unfolds into culture-based technology, molecular technology, and proteomic technology. Notably, the culture-based technology is anticipated to reach USD 7.5 billion by 2032.
 

• Culture-based technology is playing a pivotal role in addressing the global challenge of antimicrobial resistance. The emphasis on accurate pathogen identification and antimicrobial susceptibility testing aligns with efforts to combat the rising threat of drug-resistant infections.
   
• Additionally, as the prominence of culture-based technology grows, there is an increased focus on regulatory compliance and standardization. Adhering to rigorous quality standards ensures the reliability and reproducibility of results, fostering trust in these diagnostic methodologies.
   

Based on application, the blood culture tests market unfolds into bacterial infections, fungal infections, and mycobacterial infections. Notably, the bacterial infections garnered USD 4.1 billion in 2023.
 

• According to the National Institute of Health (NIH), each year, at least 1.7 million adults in the U.S. develop sepsis, and nearly 270,000 deaths occur. The number of blood infection cases per year in the U.S. have been on the rise. Thus, accurate infection diagnostics play a crucial role in mitigating the impact of infectious diseases on public health.
   
• Moreover, governments are actively engaging in awareness campaigns to educate the public about the importance of early detection and prevention of infectious diseases.
   

Based on end-use, the blood culture tests market unfolds its segmentation, encompassing the domains of diagnostic centers, hospitals, and other end-users. The diagnostic centers segment garnered a market share of 59% in 2023.
 

• The continued enhancement of research and diagnostic capabilities within hospital laboratories, paired with an increase in disposable income in developed nations, is anticipated to be a significant driving force behind the widespread utilization of blood culture tests in hospital settings. This, in turn, will contribute significantly to the expansion of the hospital segment within the blood culture tests industry.
   
• Diagnostic centers are expanding their offerings beyond conventional blood culture tests by incorporating comprehensive infectious disease panels. These panels include a spectrum of tests to identify a range of pathogens, contributing to a more thorough and targeted diagnostic approach.
   
• Collaboration with healthcare systems and hospitals is becoming more prevalent among diagnostic centers. These partnerships enhance the overall continuum of patient care, allowing for seamless sharing of information, resources, and expertise in infectious disease management.
   

U.S. blood culture tests market surpassed USD 2.2 billion in 2023 and is predicted to witness substantial market growth.
 

• Increasing healthcare investments, a rising burden of infectious and chronic diseases, and efforts to expand healthcare access contribute to the region's dynamic healthcare landscape.
   
• The rapid adoption of advanced diagnostic technologies supported by government initiatives and policies play a crucial role in accelerating market growth.
   
• Blood culture tests play a vital role in the management of sepsis. The focus on early diagnosis and intervention in sepsis cases was influencing the adoption of blood culture tests in clinical practice.
   

Blood Culture Tests Market Share

The blood culture tests industry is consolidated, with key players including Becton, Dickinson and Company, Terumo Corporation, BioMerieux SA, and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market share. For instance, in April 2022, BioMerieux SA entered into agreement with the U.S. based privately held Specific Diagnostics company that offers rapid antimicrobial susceptibility test (AST) system, delivering phenotypic AST directly from positive blood cultures. This agreement helped the company to enhance its market position.
 

Blood Culture Tests Market Companies

Some of the eminent market participants operating in the blood culture tests industry include

• Becton, Dickinson and Company
• Terumo Corporation
• bioMerieux SA
• Bruker Corporation
• T2 Biosystems Inc.
• Abbott Laboratories
• Luminex Corporation
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• Danaher Corporation
• Neogen Corporation
• Thermo Fisher Scientific Inc.
   

Blood Culture Tests Industry News

• In May 2022, BD and science-first healthcare tech company Babson Diagnostics, through the formation of a strategic agreement increased the company's reach by bringing blood sample collection into the modern healthcare environment. Through this partnership, patients would be able to obtain blood samples at home, making diagnostic testing more convenient. It is anticipated that these changes will provide a profitable environment for industry expansion.
   
• In October 2022, BD and Magnolia Medical Technologies partnered with one another to provide cutting-edge technology to hospitals across the U.S. in their efforts to mitigate blood culture contaminations. This partnership enabled the companies to enhance their customer base.
   
• In March 2023, T2 Biosystems, Inc. declared that it would upgrade its current T2Candida panel with Candida Auris detection technology. The T2Candida panel previously received approved by the U.S. FDA. Therefore, the continuous usage of modern technologies helped the company boost its market position.
   

This blood culture tests market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product

• Instruments
  • Automated blood culture systems
  • Supporting laboratory equipment
    • Incubators
    • Colony counters
    • Microscopes
    • Gram stainers 
• Consumables
  • Blood culture media
  • Assay kits & reagents
  • Blood culture accessories

Market, By Method

• Automated method
• Conventional/manual method

Market, By Technology

• Culture-based technology
• Molecular technology
• PCR
• Microarray
• PNA-FISH

• Proteomic technology

Market, By Application

• Bacterial infections
• Fungal infections
• Mycobacterial infections

Market, By End-use

• Diagnostic centers
• Hospitals
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa